Engineered immune cells take aim at stubborn blood cancers
NCT ID NCT07234110
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early study is testing a new treatment called CD5CART for people with relapsed or refractory CD5-positive blood cancers. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer cells, and then infusing them back. The main goals are to check the treatment's safety and find the best dose, while also seeing if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD5CART (a type of CAR-T cell therapy that targets the CD5 protein on cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with certain blood cancers that have not responded to standard therapies.
What could go wrong
This is a very early, small trial (18 people) focused on safety and finding the right dose. It may not work for everyone, and CAR-T therapies can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY CD5 HEMATOLOGICAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Hospital of Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••